Phase II Study of Docetaxel +/- Nintedanib in Breast Cancer

Inclusion Criteria:

* Age ≥ 18 years old
* Histologically or cytologically confirmed adenocarcinoma of the breast
* Locally recurrent or metastatic disease
* HER 2 negative status
* Requiring a first or a second-line chemotherapy for locally recurrent or metastatic disease.
* Prior first line chemotherapy not containing Docetaxel
* Measurable or evaluable disease according to RECIST 1.1 criteria
* Allowed prior chemotherapy as follows :

  * Docetaxel in the neoadjuvant or adjuvant setting is allowed provided that relapse has been observed more than 12 months after the end of docetaxel treatment
  * Bevacizumab in 1st line is allowed with a wash-out of 4 weeks, with recovery to NCI-CTCAE v3.0 toxicity
* ECOG performance status 0-1
* Adequate bone marrow, hepatic and renal functions as evidence by the following:

  * Hemoglobin ≥ 10 G/100 mL
  * Neutrophils count ≥ 1500 /mm3
  * Platelets ≥ 100 000 /mm3
  * Total bilirubin ≤ ULN (ULN:Upper Limit of Normal)
  * SGOT/SGPT ≤ 1.5 x ULN (≤ 2.5 x ULN in case of hepatic metastasis)
  * Serum alkaline phosphatase ≤ 2.5 x ULN
  * Creatinin clearance ≥ 45 ml/min or creatinin ≤ 1.5 x ULN
  * Proteinuria \< CTCAE grade 2
* Coagulation parameters: International normalised ratio (INR) ≤ 2, prothrombin time (PT) and partial thromboplastin time (PTT) ≤ 50% of deviation of institutional ULN
* Effective contraception for patients (male and female) with reproductive potential during their entire participation in the study and during 3 months after the last administration of Nintedanib or Docetaxel
* Negative pregnancy test (serum beta-HCG) performed within 1 week prior to start of study treatment in females with reproductive potential
* Patient covered by government health insurance
* Signed and dated written informed consent prior to admission to the study in accordance with ICH-GCP guidelines and to the local legislation

Exclusion Criteria:

* Concomitant hormone therapy for metastatic breast cancer
* Patients with dysphagia, or inability to swallow the tablets
* Other serious illness or medical conditions: Cardiac disease
* Unstable diabetes
* Uncontrolled hypercalcemia
* Pregnancy or breast feeding woman
* Unable for medical follow-up (geographic, social or mental reasons)
* Prior treatment with Nintedanib or any other VEGFR inhibitor
* Known hypersensitivity to the trial drugs , to their excipients, to peanut, to soya or to contrast media
* Contra indication to the use of the backbone treatment and to the comparator
* Active brain metastases (e.g. stable for \<4 weeks, no adequate previous treatment with radiotherapy, symptomatic, requiring treatment with anti-convulsants; dexamethasone therapy will be allowed if administered as stable dose for at least one month before randomisation)
* Leptomeningeal disease
* Radiographic evidence of cavitary or necrotic tumors
* Centrally located tumors with radiographic evidence (CT or MRI) of local invasion of major blood vessels
* History of clinically significant haemorrhagic or thromboembolic event in the past 6 months
* Known inherited predisposition to bleeding or thrombosis
* Significant cardiovascular diseases ( i.e. uncontrolled hypertension, unstable angina, history of infarction within the past 12 months prior to start of study treatment, congestive heart failure \> NYHA II, serious cardiac arrhythmia, pericardial effusion)
* Other malignancies within the past 5 years other than basal cell skin cancer or carcinoma in situ of the cervix
* Active serious infections in particular if requiring systemic antibiotic or antimicrobial therapy
* Active or chronic hepatitis C and/or B infection
* Active alcohol or drug abuse
* Significant weight loss (\> 10% of BW) within past 6 months prior to inclusion into the trial